Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Denali Therapeutics Inc (NASDAQ: DNLI) was $23.95 for the day, up 4.04% from the previous closing price of $23.02. In other words, the price has increased by $4.04 from its previous closing price. On the day, 0.58 million shares were traded. DNLI stock price reached its highest trading level at $24.14 during the session, while it also had its lowest trading level at $22.84.
Ratios:
Our analysis of DNLI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.46 and its Current Ratio is at 12.46. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $32.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 13 ’24 when Schuth Alexander O. sold 2,272 shares for $22.89 per share. The transaction valued at 52,006 led to the insider holds 186,419 shares of the business.
Ho Carole sold 2,337 shares of DNLI for $53,494 on Aug 13 ’24. The Chief Medical Officer now owns 141,268 shares after completing the transaction at $22.89 per share. On Aug 13 ’24, another insider, Schuth Alexander O., who serves as the Officer of the company, bought 2,272 shares for $22.89 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 3428801792 and an Enterprise Value of 2581516032. For the stock, the TTM Price-to-Sale (P/S) ratio is 2699.75 while its Price-to-Book (P/B) ratio in mrq is 2.47. Its current Enterprise Value per Revenue stands at 2037.503 whereas that against EBITDA is -5.219.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $25.24, while it has fallen to a 52-week low of $14.56. The 50-Day Moving Average of the stock is 6.99%, while the 200-Day Moving Average is calculated to be 21.12%.
Shares Statistics:
DNLI traded an average of 1.15M shares per day over the past three months and 824290 shares per day over the past ten days. A total of 138.39M shares are outstanding, with a floating share count of 119.04M. Insiders hold about 16.67% of the company’s shares, while institutions hold 84.65% stake in the company. Shares short for DNLI as of 1722384000 were 7186932 with a Short Ratio of 6.25, compared to 1719532800 on 7427626. Therefore, it implies a Short% of Shares Outstanding of 7186932 and a Short% of Float of 5.88.
